[1] Ruiz-Ortega M, Rayego-Mateos S, Lamas S, et al., Targeting the progression of chronic kidney disease[J], (2020).
[2] Ortiz A %J EMBO molecular medicine, PDGFR-β and kidney fibrosis[J], (2020) e11729.
[3] Matsushita K, Ballew SH, Coresh J, et al., Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data[J], 5(9) (2017) 718-728.
[4] Tuttle KR, Lakshmanan MC, Rayner B, et al., Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial[J], 6(8) (2018) 605-617.
[5] Beddhu S, Greene T, Boucher R, et al., Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials[J], 6(7) (2018) 555-563.
[6] Waikar SS, Srivastava A, Palsson R, et al., Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression[J], 179(4) (2019) 542-551.
[7] Tang J, Yao D, Yan H, et al., The Role of MicroRNAs in the Pathogenesis of Diabetic Nephropathy[J], 2019 (2019) 8719060.
[8] Jia Y, Zheng Z, Guan M, et al., Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells[J], 50(5) (2018) 56.
[9] Chung AC, Lan HY %J Frontiers in physiology, MicroRNAs in renal fibrosis[J], 6 (2015) 50.
[10] Wang B, Komers R, Carew R, et al., Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis[J], 23(2) (2012) 252-65.
[11] Fang Y, Yu X, Liu Y, et al., miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation[J], 304(10) (2013) F1274-82.
[12] He Y, Huang C, Lin X, et al., MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases[J], 95(7) (2013) 1355-9.
[13] Ramdas V, McBride M, Denby L, et al., Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29[J], 183(6) (2013) 1885-1896.
[14] Cao G, Li S, Shi H, et al., Schisandrin B attenuates renal fibrosis via miR-30e-mediated inhibition of EMT[J], 385 (2019) 114769.
[15] Yang R, Xu X, Li H, et al., p53 induces miR199a-3p to suppress SOCS7 for STAT3 activation and renal fibrosis in UUO[J], 7 (2017) 43409.
[16] Xia H, Ooi LL, Hui KM %J Hepatology, MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer[J], 58(2) (2013) 629-41.
[17] Faherty N, Curran SP, O'Donovan H, et al., CCN2/CTGF increases expression of miR-302 microRNAs, which target the TGFβ type II receptor with implications for nephropathic cell phenotypes[J], 125 (2012) 5621-9.
[18] Tompkins AJ, Chatterjee D, Maddox M, et al., The emergence of extracellular vesicles in urology: fertility, cancer, biomarkers and targeted pharmacotherapy[J], 4 (2015) 23815.
[19] Khan SR, Rodriguez DE, Gower LB, et al., Association of Randall plaque with collagen fibers and membrane vesicles[J], 187(3) (2012) 1094-100.
[20] Beltrami C, Besnier M, Shantikumar S, et al., Human Pericardial Fluid Contains Exosomes Enriched with Cardiovascular-Expressed MicroRNAs and Promotes Therapeutic Angiogenesis[J], 25(3) (2017) 679-693.
[21] Wang B, Zhang C, Zhang A, et al., MicroRNA-23a and MicroRNA-27a Mimic Exercise by Ameliorating CKD-Induced Muscle Atrophy[J], 28(9) (2017) 2631-2640.
[22] B. Wang, C. Zhang, A. Zhang, et al., MicroRNA-23a and MicroRNA-27a Mimic Exercise by Ameliorating CKD-Induced Muscle Atrophy[J], J Am Soc Nephrol 28(9) (2017) 2631-2640.
[23] Chen DQ, Cao G, Chen H, et al., Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan[J], 10(1) (2019) 1476.
[24] Roediger B, Lee Q, Tikoo S, et al., An Atypical Parvovirus Drives Chronic Tubulointerstitial Nephropathy and Kidney Fibrosis[J], 175(2) (2018) 530-543.e24.
[25] Romagnani P, Remuzzi G, Glassock R, et al., Chronic kidney disease[J], 3 (2017) 17088.
[26] Zhou T, Luo M, Cai W, et al., Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ[J], 31 (2018) 217-225.
[27] von Toerne C, Schmidt C, Adams J, et al., Wnt pathway regulation in chronic renal allograft damage[J], 9(10) (2009) 2223-39.
[28] Meng XM, Nikolic-Paterson DJ, Lan HY %J Nature reviews. Nephrology, TGF-β: the master regulator of fibrosis[J], 12(6) (2016) 325-38.
[29] Wang P, Luo ML, Song E, et al., lnc-TSILong noncoding RNA inhibits renal fibrogenesis by negatively regulating the TGF-β/Smad3 pathway[J], 10(462) (2018).
[30] Solé C, Cortés-Hernández J, Felip ML, et al., miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis[J], 30(9) (2015) 1488-96.
[31] Zhang A, Li M, Wang B, et al., miRNA-23a/27a attenuates muscle atrophy and renal fibrosis through muscle-kidney crosstalk[J], 9(4) (2018) 755-770.
[32] Wang B, Yao K, Huuskes BM, et al., Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis[J], 24(7) (2016) 1290-301.